Jerri Rook , Ph.D.
B.A. Biology/Chemistry, Drury University, 2000
Ph.D. Pharmacology, University of Kansas Medical Center, 2008
Biosketch and Research Interests
Dr. Rook is a Research Instructor in the Department of Pharmacology at Vanderbilt University in the Vanderbilt Center for Neuroscience Drug Discovery. She received her Ph.D. degree in Pharmacology from the University of Kansas Medical Center in 2008 where she was supported by the KUMC Biomedical Research Training Program Award. She then pursued her postdoctoral studies in the laboratory of P. Jeffrey Conn, Ph.D. at Vanderbilt University where she was a postdoctoral member of the Vanderbilt Brain Institute. Dr. Rook has served as an author on several primary research articles in peer-reviewed scientific journals and frequently presents her work at both national and international meetings. She is currently the member of the American Society for Pharmacology and Experimental Therapeutics, Society for Neuroscience, and International Society for Neurochemistry. Dr. Rook has received multiple awards including the Ruth L. Kirschstein National Research Service Award from the National Institute of Mental Health in 2009, the Alzheimer's Drug Discovery Foundation and Charles River Laboratories International, Inc. 2011 partnership award, and is the recent recipient of the Edward N. & Della L. Thome Memorial Foundation award program in Alzheimer's disease drug discovery research.
Dr. Rook is a highly trained behavioral and systems neuropharmacologist who has a great deal of expertise with the use of biochemistry, molecular biology, behavioral pharmacology and imaging techniques to study the in vivo effects of GPCR ligands in preclinical animal models. She has made a number of contributions to the understanding of the roles of mGlu5 in the regulation of brain function and behavior and in the development of novel therapeutic strategies for the treatment of central nervous system disorders. Currently, Dr. Rook is focused on the discovery of novel therapeutic strategies for the treatment of cognitive deficits associated with schizophrenia and Alzheimer’s disease.
Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ. 2012. Unique signaling profiles of positive allosteric modulators of mGlu5 determine differences in in vivo activity. Biological Psychiatry. PMID: 23140665
Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ. 2012. Investigating mGlu5 Allosteric Modulator Cooperativity, Affinity and Agonism: Enriching Structure-function Studies and Structure-activity Relationships. Molecular Pharmacology. 82(5):860-75. PMID: 22863693
Noetzel MJ*, Rook JM*, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ. 2012. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Molecular Pharmacology. 81(2):120-33. PMID: 22021324
*authors contributed equally to this work
Sheffler DJ, Gregory KJ, Rook JM, Conn PJ. 2011. Allosteric modulation of metabotropic glutamate receptors. In: Advances in Pharmacology. 62:37-77. PMID: 21907906
Tantawy MN, Peterson TE, Jones CK, Johnson K, Rook JM, Conn PJ, Baldwin RM, Ansari MS, Kessler RM. 2011. Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot. Synapse. 65(11):1173-80. PMID: 21584868
Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ. 2010. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Molecular Pharmacology. 78:1105-1123. PMID: 20923853
Sharma S, Kedrowski J, Rook JM, Barrett RS, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW. 2009. Discovery of molecular switches that modulate modes of mGluR5 pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- or 5-(phenylethynyl) pyrimidines. Journal of Medicinal Chemistry. 23;52(14):4103-6. PMID: 19537763
Rook JM, Hasan W, McCarson KE. 2009. Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression. Biochemical Pharmacology. 77(11):1747-55. PMID: 19428329
Rook JM, Hasan W, McCarson KE. 2008. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology. 109(1):130-6. PMID: 18580183
Rook JM, McCarson, KE. 2007. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochemical Pharmacology 74(5):752-7. PMID: 17632084
Roy RN, Carlsten JA, Niederschmidt J, Good WS, Rook JM, Brewe C, Kilker AJ, Roy LN, Kuhler KM. 1997. Buffers for the physiological pH range: thermodynamic constants of substituted aminopropanesulfonic acids from 5 to 55ºC. Journal of Solution Chemistry. 26; (3) 309-17
Roy RN, Moore CP, Carlsten JA, Good WS, Harris P, Rook JM, Roy LN, Kuhler KM. 1997. Second dissociation constant of two substituted aminomethanesulfonic acids in water from 5 to 55ºC. Journal of Solution Chemistry. 26; (12) 1209-16